Several studies have shown heterogeneity in lung cancer, with parallel existence of multiple subclones characterized by their own specific mutational landscape. The extent to which minor clones become dominant in distinct metastasis is not clear. The aim of our study was to gain insight in the evolution pattern of lung cancer by investigating genomic heterogeneity between primary tumor and its distant metastases. Whole exome sequencing (WES) was performed on 24 tumor and five normal samples of two small cell lung carcinoma (SCLC) and three non-SCLC (NSCLC) patients. Validation of somatic variants in these 24 and screening of 33 additional samples was done by single primer enrichment technology. For each of the three NSCLC patients, about half of the mutations were shared between all tumor samples, whereas for SCLC patients, this percentage was around 95. Independent validation of the non-ubiquitous mutations confirmed the WES data for the vast majority of the variants. Phylogenetic trees indicated more distance between the tumor samples of the NSCLC patients as compared to the SCLC patients. Analysis of 30 independent DNA samples of 16 biopsies used for WES revealed a low degree of intra-tumor heterogeneity of the selected sets of mutations. In the primary tumors of all five patients, variable percentages (19-67%) of the seemingly metastases-specific mutations were present albeit at low read frequencies. Patients with advanced NSCLC have a high percentage of non-ubiquitous mutations indicative of branched evolution. In contrast, the low degree of heterogeneity in SCLC suggests a parallel and linear model of evolution.
Introduction
Lung cancer is the main cause of cancer-related deaths in the world with approximately 1.4 million patients per year (1) . Two main histological subtypes are recognized with approximately 15% of the patients presenting with small cell lung carcinoma (SCLC) and 85% with non-small cell lung carcinoma (NSCLC). The latter group is further subdivided into three subgroups, i.e. large cell carcinoma (LCC), squamous cell carcinoma and adenocarcinoma (AC) (2, 3) .
Recent developments in next generation sequencing techniques in combination with improved bioinformatics tools have greatly advanced the field of tumor genetics. These developments have resulted in a better understanding of tumor cell evolution; i.e. linear versus non-linear or branched evolution (4, 5) . In the linear model, tumor cells acquire sequential genomic changes (mutations or copy number variations (CNVs)) over time and the clone that contains most favorable genomic changes will become dominant (6) . The branching evolution model assumes development of multiple parallel tumor cell clones that all acquire specific genomic aberrations over time. These tumor clones exist independently within the tumor mass (4, 6, 7) . A branched evolution has been shown in pancreatic (8, 9) , clear cell renal cancer (10, 11) , breast cancer (12) and lung cancer (13) . A branched evolution results in extensive subclonal diversity and intra-tumor heterogeneity. In contrast, a linear evolution results in a more homogeneous tumor mass. Linear evolution in combination with an incomplete clonal sweep, i.e. failure of a subclone to completely outcompete its ancestral clones, may result in a lower degree of intra-tumor heterogeneity (14, 15) .
Two models have been suggested to contribute to intratumor heterogeneity; genetic and non-genetic (16) . In the genetic model, a monoclonal tumor population can become heterogeneous due to genomic instability. In the non-genetic model, factors like availability of nutrition, alteration of oxygen level, interaction of tumor cells with neighboring cells, presence of cancer stem cells and location within the primary tumor can lead to preferential outgrowth of some cell populations resulting in intra-tumor heterogeneity (16) .
The observed evolution patterns might be affected by experimental factors such as sampling bias, and by biological factors such as exposure to carcinogens, drug treatment and tumor microenvironment (4, 6) . So far, most studies have focused on analysis of single biopsies of the tumor mass, which could result in underestimation of the actual degree of tumor heterogeneity.
The aim of this study was to gain insight in the evolution pattern of lung cancer by studying genomic heterogeneity in the primary tumor and its metastases by whole exome sequencing (WES) of samples derived from multiple tumor locations in five lung cancer patients. WES data were validated using targeted re-sequencing of non-ubiquitous somatic mutations. In addition, we used the validation data to identify presence of minor metastasis-resembling clones in the primary tumor samples.
Materials and methods

Samples
Multiple tumor samples of five deceased lung cancer patients undergoing autopsy were included in this study. One patient presented with LCC, one with squamous cell carcinoma, one with AC and two with SCLC. These five patients were selected from a larger group of patients based on having stage IV lung cancer with metastases in mediastinal lymph nodes and in different visceral organs, in combination with having frozen tissue samples of normal tissue, primary tumor location and at least two metastatic locations. Tissue samples of normal, primary lung tumor and multiple metastatic locations were all obtained at autopsy with exception of patient #1 for whom we also included a primary tumor sample obtained at diagnosis. Autopsy was done within 6 h after death. All tissue samples were snap frozen. In total, 45 frozen tissue blocks were obtained, of which 29 (5 normal and 24 tumor blocks) were subjected to WES. The additional tumor blocks (n = 16) were used in the validation and heterogeneity analyses (Supplementary Tables 1 and 2 , available at Carcinogenesis Online). Each patient gave informed consent for this study. All procedures and protocols were performed according to the guidelines of the Medical Ethics Committee.
Immunohistochemistry
Hematoxylin and eosin (HE) sections were made for each sample to confirm diagnosis and to determine the histological subtype based on the WHO classification. In addition, HE sections were made for each normal sample, which was derived from normal lung for patients #1 and #3, normal liver for patient #2, and normal brain for patients #4 and #5. This classification was confirmed in diagnostic biopsies as part of the routine diagnostic procedure using mucin stains and immunohistochemistry for p40/p63, TTF1 and CK5-6 for NSCLC and with CD56, synaptophysin and chromogranin for SCLC.
To exclude the presence of a minor population of tumor cells in frozen normal tissue samples of the SCLC patients, immunostaining was performed using anti-cytokeratin (clones AE1/AE3, Dako, Glostrup, Denmark) and anti-CD56 (Becton Dickinson, NJ) antibodies using standard protocols. Anti-Cytokeratin was added as an extra precaution to identify atypical cells in particular of use in the brain tissue as normal control. Briefly, 3 µm frozen sections were fixed in acetone for 10 min. Next, slides were incubated with primary antibody at room temperature (RT) for 1 h (dilutions were 1:100 and 1:50 for Cytokeratin and CD56, respectively). After blocking of endogenous peroxidase activity, secondary and tertiary antibodies were incubated at RT for 30 min and slides were stained with AEC (3-amino-9-ethylcarbazole) and hematoxylin.
DNA isolation and WES
For the WES procedure, we aimed to isolate DNA from a tissue sample with at least 80% tumor cells. For blocks with more than 80% tumor content, we used the complete tissue section, otherwise we performed macro-dissection or laser microdissection (LMD6000, Leica, Wetzlar, Germany). For validation of non-ubiquitous mutations, we used both total tissue sections and laser microdissected tissue for DNA isolation using standard laboratory procedures. WES was carried out using standardized protocols of the UMCG genome facility as described previously (17) . Briefly, 0.3-3 μg genomic DNA was randomly fragmented by ultrasonic nebulization (K7025-05, Life Technologies, Paisly, UK). Library preparation was done using Agilent library prep kits (Agilent technologies, Santa Clara, CA) for samples with high input DNA (>500 ng) and with Mondrian library prep kits (NuGEN Technologies, San Carlos, CA) for samples with low DNA input (<500 ng). For both procedures, fragments of ~300 bp were isolated using the PerkinElmer labchip XT gel system. Enrichment of exons was for both approaches performed using the Agilent SureSelect All exon V5 kit (Agilent technologies, Santa Clara, CA) on equimolar pools of PCR products of four independent samples. Purified samples were subjected to paired-end sequencing on the HiSeq2500. Image Files were processed using standard Illumina® base calling software and subsequently de-multiplexed (Illumina Inc., San Diego, CA).
Reads were aligned to the human 1000 genomes reference based on the GRCh37 build using BWA 5.9rc (18) . Picard tools were used for format conversion and marking duplicate reads. Genome Analysis Toolkit (GATK1) was used for indel realignment and base score quality recalibration (BSQR) (19) by Molgenis Compute 4 (20) . After using custom scripts in the VCF tools library (21) for the VCF files, variant calling was done using the GATK unified genotyper. Annotation of the variants was performed using snpeff/ snpsift 3.5 (22) with the ensembl release 74 gene annotations (http://www. ensembl.org/index.html), dbNSFP2.3 (23) , and GATK with annotations from the Database of Single Nucleotide Polymorphisms (dbSNP) Bethesda (MD): National Center for Biotechnology Information, National Library of Medicine (dbSNP Build ID: 137) and CosmicCodingMuts_v62 (24) . In addition to the snpeff and snpsift, we also annotated the variants using ANNOVAR (25) . A combination of three different filtering steps has been applied on the list of mutations. We removed variants that (1) were present in the Caucasian based 1000-Genome (26) with allele frequency larger than 0.2% (2), map in non-coding regions and (3) were synonymous.
Personal variants in the tumor were removed based on a z-score ≥ −3 in normal samples using the formula: Z = (allele frequency − 0.5)/SD × (SQRT of total reads). The remaining somatic variants were included in the downstream analysis.
Correction for normal cell admixture
To correct for admixture of normal cells, we deduced the approximate percentage of admixture of normal cells based on the mutant read frequency (MRF) of the true mutations. We based these calculations on the mean MRF of the somatic mutations in the 25-75% interquartile range assuming that these represent heterozygous mutations for which the MRF should be 0.5 in a sample with 100% tumor cells. The lower and higher quartiles were excluded as they might be derived from gene loci that have copy number gain or loss or represent homozygous mutations or minor clones. The mean value multiplied by 2 was considered as an estimation of the 
High-and low-confidence mutations
Criteria to call mutations as high-or low-confidence were based on the mutant allele count and frequency after correction for normal cell admixture. Mutations with a mutant read count ≥5 and a MRF ≥20% were denoted as high-confidence mutations. Mutations with mutant read count of 1-4 or a MRF <20% were referred to as low-confidence. In the absence of mutant reads and a total number of reads <30, the presumed mutation was called inconclusive (high chance of being absent). If the mutant read count was zero and the total read was ≥30, the presumed mutation was called absent.
Overlap with lung cancer mutated genes from COSMIC and other sources
The list of genes mutated in the primary tumors (n = 1074) was compared with the top 20 most commonly mutated genes in lung cancer according to the COSMIC database v.73 and to the list of most commonly mutated genes (n = 64) of five studies on lung cancer including 110-230 tumor samples (27) (28) (29) (30) (31) . Overlap of genes mutated in these lists and in one of the five primary lung tumors was identified by using an online Venn diagram tool (http://bioinformatics.psb.ugent.be/webtools/Venn).
Validation of somatic mutations and heterogeneity analysis using single primer enrichment technology
To confirm inter-tumor heterogeneity, all non-ubiquitous single nucleotide variants were validated using the Ovation© target enrichment procedure that is based on the single primer enrichment technology (SPET) (NuGEN Technologies, San Carlos, CA). We included five ubiquitous mutations for each patient as positive controls. This resulted in a selection of 467 SNVs. In total, we re-analyzed 228 mutations of tumor samples of patient #1, 152 of patient #2, 47 of patient #3, 23 of patient #4 and 17 of patient #5. In total, 57 DNA tumor samples originating from 40 tumor blocks were analyzed for validation and heterogeneity assessment. For some of the tumor blocks, we did multiple independent DNA isolations. It should be noted that all DNA samples were analyzed for all selected variants. Ovation© target enrichment system landing-probes were designed by NuGEN at a distance of 10-20 nucleotides downstream and upstream of each single nucleotide variant to be validated. In a few cases, two variants were too close together to be able to design separate landing probes. For 459 of the variants, two landing probes could be designed. Five variants were targeted by only one landing probe. For three variants, no landing probes could be designed. Validation could be performed for 464 somatic mutations. Target enrichment and library preparation was done according to the manufacturer's protocol (NuGEN Technologies, San Carlos, CA). Briefly, genomic DNA was fragmented, end-repaired and ligated with forward barcoded adaptors, which was followed by a beads purification step. The barcoded adaptor contained both a 8-nt sample-specific barcode and a 6-nt molecular barcode. The latter was used to identify and remove duplicate reads. Samples were combined for multiplex target enrichment. The reverse adaptor was annealed to the target regions and extended. Library amplification step was done using 22-25 PCR cycles depending on the quality of DNA pools as determined by qPCR; followed by beads purification and sequencing.
Validation
We did not discriminate between low and high-confidence mutations for the independent validation, as we did not perform laser micro-dissection for all samples and tumor percentage might be relatively low at least in part of the samples. We considered a mutation as validated when the MRF was ≥0.05 and the total read count ≥30. We calculated the percentage of validated mutations for each of the four categories, i.e. high-confidence, low-confidence, inconclusive and absent, separately based on the total number of mutations with enough coverage.
Heterogeneity analyses
Intra-tumor heterogeneity was assessed for tumors for which additional blocks or subsequent tissue sections were available for DNA isolation and targeted sequencing. We included all variant positions with a total read count of ≥30 in all samples of the patient. We calculated the percentage of SPET validated mutations in the additional samples of the same tumor using the original WES sample as a reference.
Identification of metastases-specific mutations in the primary tumor samples
Metastases-specific mutations were called in the primary tumor samples based on presence of at least two mutant reads in the primary tumor samples. Presence of such mutations in the primary tumor indicated presence of minor metastasis resembling clones.
Phylogenetic tree
Hierarchical cluster analysis was done using R 3.3.1 and the APE 3.5 package using the binary distance matrix containing presence or absence of somatic mutations based on the combined results of the WES and SPET analysis to create phylogenetic trees (32, 33) .
Intra-and inter-tumor heterogeneity definition
Heterogeneity within one specific location has been referred to as 'intra-tumor heterogeneity' and heterogeneity between different tumor locations within a single patient has been referred to as 'inter-tumor heterogeneity.'
Results
Patient characteristics
All patients presented as stage IV lung cancer. Four of the five lung cancer patients (#1, #2, #4 and #5) were smokers and had chronic obstructive pulmonary disease (COPD). Patient #3 was the only non-smoker and had advanced adenocarcinoma of the lung (Supplementary Table 1 , available at Carcinogenesis Online). Patient #1, diagnosed with LCC, had the longest interval between diagnosis and death, i.e. more than 6 years, whereas patient #5, diagnosed with SCLC had the shortest interval from diagnosis to death, i.e. only 6 days ( Figure 1 ). Treatments were cisplatin and gemcitabine in the patient with squamous cell carcinoma (#2), cisplatin and pemetrexed for AC patient (#3), cisplatin and etoposide for both patients with SCLC (#4 and #5) and surgery for the poorly differentiated LCC (#1). Multiple samples of the primary tumor, different metastatic sites and normal tissue were obtained from each patient at autopsy (Supplementary Tables 1  and 2 , available at Carcinogenesis Online). In addition, we obtained a sample from the primary tumor at diagnosis from patient #1.
WES and Mutation detection
WES resulted in a mean coverage ranging from 43× to 89× and a >20× coverage ranging from 83 to 96% of the target region (Supplementary Table 3 , available at Carcinogenesis Online). Based on a z-score of >−3, 31-34% of the variants were considered as personal variants in patients #1, #2, #4 and #5. In patient #3, 74% of the identified variants were denoted as personal variants (Supplementary Table 4 , available at Carcinogenesis Online). This much higher percentage of personal variants is probably due to the non-Caucasian background of this patient. The number of somatic mutations ranged from 92 (patient #3) to 462 (patient #1) (Supplementary Tables 3 and 5 , available at Carcinogenesis Online).
The mean of interquartile mutant read frequencies ranged from 49 (SD = 0.05) to 18 (SD = 0.02) indicating an admixture of normal cells ranging from 2 to 64% (Supplementary Table 3 and Supplementary Figure 1 , available at Carcinogenesis Online).
To allow a reliable comparison of shared and sample-specific somatic mutations, we corrected the MRF for the estimated admixture of normal cells. In total, we found 1511 unique somatic mutations in the five patients. SNPEFF, SIFT, MetaSVM, Polyphen2, CADD, GERP++ and PROVEAN scores of all mutations are given in Supplementary Table 5, available at Carcinogenesis Online.
Comparison of the genes mutated in at least one of the five primary tumors to the top 20 most commonly mutated genes in lung cancer present in the COSMIC database revealed that 11 out of 20, including TP53, KRAS, RB1 and ALK, were mutated in one or more of the five primary tumor samples in this study (Supplementary Table 6 , available at Carcinogenesis Online). Most of these mutations were ubiquitous. Sixteen out of 64 genes related to lung cancer according to five large studies (27) (28) (29) (30) (31) were mutated in at least one of the five primary tumor samples (Supplementary Table 7 , available at Carcinogenesis Online).
Inter-tumor heterogeneity based on WES
A complete list of the ubiquitous and non-ubiquitous somatic mutations detected by WES is given in Supplementary Table 5 , available at Carcinogenesis Online. We found 462 mutations in 430 genes in patient #1 with LCC. Approximately, 50% (n = 237) of these mutations were ubiquitous, 67 (14.5%) were specific for the primary tumor and 129 (27.9%) were present in one or more metastases (metastases-specific mutations). The remaining 29 (6.3%) mutations were shared between the primary and one of the two metastases (Figure 2A) . The tumor samples of patient #2 with squamous cell carcinoma contained a total of 331 somatic mutations in 300 genes. More than half of these mutations (55%) were ubiquitous and 23 (7%) of the mutations were specific for the primary tumor. One hundred and three (31%) of the mutations were metastases-specific. The remaining 23 (7%) mutations were shared between primary tumor and at least one of the metastasis. The tumor samples of patient #3 with AC had 92 mutations in 91 genes, of which 49 (53.3%) were present in all samples. No primary tumor-specific mutations were observed in this patient. Thirty-one (33.7%) mutations were metastases-specific, while 12 (13%) mutations were shared between primary tumor and at least one of the metastasis. To explore potential differences in the impact of ubiquitous versus non-ubiquitous mutations in the three NSCLC patients, we calculated the percentage of damaging and non-damaging mutations for all seven annotation tools. This revealed no differences between the impact of ubiquitous and non-ubiquitous mutations (Supplementary Figure 2 , available at Carcinogenesis Online).
In SCLC patient #4, we identified 359 mutations in 345 genes (Figure 2A ). Ninety-five percent (n = 341) of the somatic mutations were present in all tumor samples. In addition, we found four mutations to be specific for the primary tumor. In the metastasis, we found four mutations to be specific for the mediastinal lymph node, one mutation specific for liver and one for the adrenal metastasis. In SCLC patient #5, we identified 271 mutations in 249 genes. Two hundred and fifty nine (95.6%) of the somatic mutations were present in all tumor samples. No primary specific mutations were identified in this patient. Four mutations were metastases-specific and the other eight mutations were shared between the primary tumor and at least one of the metastases.
Comparison of all liver and all lymph nodes samples of four patients revealed no organ-specific mutated gene.
SPET analysis of all non-ubiquitous and five ubiquitous mutations per patient resulted in a mean coverage of 97-288 and a 50× coverage ranging from 77 to 95% for the five patients (Supplementary Table 4 , available at Carcinogenesis Online). Using this approach, we confirmed presence of 'high-confidence' mutations in more than 99%. The presumed mutations called as 'absent' in the WES analysis were indeed absent in more than 99% of them (Table 1) . Almost all positions (99.7%) referred to as 'inconclusive' in the WES study due to lower coverage, turned out to be absent. Mutations referred to as 'low-confidence' in the WES study were confirmed in only about 30% of the cases, probably due to the mild criteria (low MRF) used for calling variants in this category.
Mutation pattern after integration with validation results
The percentage of metastases-specific mutations based on the combined WES and SPET results, was significantly higher in the metastasis of the three NSCLC patients as compared to the percentages in the metastases of the two SCLC patients (P < 0.01) ( Figure 2B ). This indicates much more inter-tumor heterogeneity in NSCLC. Consistent with these findings, we showed a significantly higher percentage of ubiquitous mutations (>95%) in SCLC as compared to NSCLC (around 50%) (P < 0.01) ( Figure 2C ). Phylogenetic trees confirmed the larger genetic distance between primary tumor and different metastases in NSCLC as compared to SCLC patients ( Figure 2D ).
Intra-tumor heterogeneity based on validated mutations
We used targeted re-sequencing to determine intra-tumor heterogeneity in 30 additional DNA samples obtained from 16 of the samples used for WES. More than 75% of the selected WESbased mutations were present in the additional samples, with no obvious differences between NSCLC and SCLC patients. These analyses revealed an overall low degree of intra-tumor heterogeneity for the selected sets of mutations ( Figure 3 and Supplementary Table 8, available at Carcinogenesis Online).
Identification of metastases-specific mutations in the primary tumor samples
Twenty-one of the 110 WES-based seemingly metastasesspecific mutations (19.1%) could be detected at low read frequencies in one or more of the primary samples obtained at time of diagnosis of patient #1 using the targeted re-sequencing approach. In the sample of the primary tumor obtained at autopsy of this patient, the mutation pattern was more similar to the lymph node metastasis (Figure 3) . In NSCLC patients #2 and #3 these percentages were 65.7% (65/99) and 27.6% (8/29), respectively. In the SCLC patients, 2 out of 8 and 2 out of 3 metastases-specific mutations were present at low read frequencies in the primary tumors of patients #4 and #5, respectively ( Figure 3 and Supplementary Table 9 , available at Carcinogenesis Online).
Discussion
The aim of this study was to explore tumor heterogeneity by comparing the mutation patterns of tumors obtained from different locations within a patient. We observed significantly more heterogeneity between the primary tumor and the different metastatic sites (inter-tumor heterogeneity) in NSCLC compared to SCLC patients. Moreover, we detected a proportion of the seemingly metastases-specific mutations in the primary tumors of all five patients by targeted re-sequencing.
About 50% of the somatic mutations in the three NSCLC patients are non-ubiquitous, which indicates a marked degree of inter-tumor heterogeneity and an ongoing evolution of the tumor cells over time. Presence of tumor location-specific mutations has been shown previously in pancreatic cancer (9) . The high percentage of non-ubiquitous mutations in NSCLC patients suggests a branched evolution model and implies that the ubiquitous mutations may not be sufficient to induce development of metastasis. Thus, NSCLC tumor cells need time to acquire additional genomic aberrations enabling them to migrate and survive in a new environment. The ubiquitous mutations most likely originate from founder clones and might be associated with tumor formation. However, overall no differences were observed between the predicted impact of the mutations on the protein for the ubiquitous as compared to the non-ubiquitous mutations.
In SCLC, almost all mutations were ubiquitous indicating a homogenous nature of the tumor mass at different anatomical locations within a patient resembling a linear evolution model. The homogeneous nature may be indicative of the short-time interval between tumor formation and the parallel development of multiple distant metastases. This finding is consistent with the aggressive nature of SCLC. The highly similar mutation profile of the primary tumor as compared to the metastasis suggests that the dominant clone of the primary tumor has already all the characteristics needed for development of the metastases. Overall, our data suggests a branched model of evolution of NSCLC and linear in SCLC, which is also reflected in the phylogenetic trees.
Analysis of additional samples of both the NSCLC and SCLC patients, i.e. subsequent tissue sections or additional tissue samples, for 16 of the 24 tumor samples included in the WES analyses revealed mutation patterns highly similar to the original WES sample. This indicates an overall low degree of intratumor heterogeneity for the selected non-ubiquitous mutations. However, the number of samples was limited, and the samples were mostly obtained from the same area as the samples used for WES. In two previous studies of 73 multiregional primary lung tumor samples of 18 NSCLC patients, variable degrees of intra-tumor heterogeneity and coexistence of several subclones within the primary tumors have been reported (13, 34) . The differences of our intra-tumor heterogeneity results with these two studies might be related to our specific focus on WES-based non-ubiquitous mutations and on the relative close vicinity of the additional tumor samples compared to the initial WES sample. In our study, the degree of intra-tumor heterogeneity may have been underestimated.
A proportion of the WES-based seemingly metastases-specific mutations could be detected in the primary tumors of the NSCLC and SCLC patients albeit as minor clones in the targeted re-sequencing analysis. This indicates that the metastasis seeding clones were already present in the primary tumor sample. This finding is consistent with the results of Yachida et al. (9) , who showed presence of metastasis seeding subclones in primary pancreatic tumors of all seven patients. Even for patient #1, with the primary tumor sampled at diagnosis 6-year before autopsy, we were still able to identify some of the metastasesspecific mutations in the primary tumor. The mutation pattern of the primary tumor sample obtained at autopsy more closely resembled the metastases than the primary tumor at diagnosis for the subset of mutations included in the targeted re-sequencing approach. This finding together with the high percentage of ubiquitous mutations in the primary tumor at diagnosis identified by WES suggests that a clone within the primary tumor at diagnosis caused the relapse and the metastases in this patient. Despite the relative low number of metastases-specific mutations in the two SCLC patients, we were able to confirm presence of part of them in the primary tumor samples of both patients. Tumor heterogeneity, as observed in our study, can have therapeutic implications for treatment of patients. Driver mutations found as major clones in one part of the tumor might be present as minor clones or even be completely absent in another part of the tumor (13) . This indicates that analysis of a single biopsy might not be sufficient for diagnostic purposes. In contrast, Zhang et al. (34) concluded that a single biopsy is sufficient for clinical evaluation based on results of a study of 11 localized AC lung patients. These opposing conclusions might be related to differences in read depth that might or might not allow detection of minor clones. Overall, there is ample evidence for the presence of metastatic ancestor or resistant subclones within the primary tumor (8, 9, (35) (36) (37) (38) (39) (40) . These subclones may become dominant during further tumor development and selective pressure due to treatment.
A high degree of tumor heterogeneity will increase the chance of resistant clones being already present at start of treatment. On the other hand, a high degree of heterogeneity may also be indicative of a relative high mutation rate within the tumor cells and thus of an increased chance of developing drug resistance-inducing mutations. Thus, inclusion of multiple samples from different geographical regions of the primary tumor and applying targeted next generation sequencing tests at high read depth should be considered to increase the probability to detect minor therapy resistant genomic aberrations. For selecting the most optimal primary treatment one needs to know the presence of trunk mutations that are drivers and druggable.
In conclusion, the high number of non-ubiquitous mutations in NSCLC indicates an ongoing and branched evolution with a propagation of many different subclones. In contrast, the low number of non-ubiquitous mutations in SCLC suggests a parallel and linear model of evolution. These data suggest that characterization of multiple regions of NSCLC tumors might be important to improve treatment planning in a clinical setting. LDM was performed, if DNA used for WES originated from a LDM sample. The first number in each sample name indicates a tissue block and the second number after 'dash' symbol shows the subsequent sections for independent DNA isolation.
